BidaskClub cut shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) from a strong-buy rating to a buy rating in a report released on Thursday morning.

A number of other research analysts have also recently weighed in on the company. Jefferies Group LLC restated a buy rating and issued a $11.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 26th. Cantor Fitzgerald set a $21.00 price target on Abeona Therapeutics and gave the company a buy rating in a research report on Tuesday, July 18th. FBR & Co restated a buy rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 5th. Zacks Investment Research upgraded Abeona Therapeutics from a sell rating to a hold rating in a research report on Friday, June 9th. Finally, Maxim Group restated a buy rating and issued a $14.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 12th. Eight research analysts have rated the stock with a buy rating, Abeona Therapeutics presently has an average rating of Buy and a consensus price target of $17.86.

Shares of Abeona Therapeutics (ABEO) opened at 8.75 on Thursday. The firm’s market capitalization is $352.23 million. Abeona Therapeutics has a 52 week low of $2.54 and a 52 week high of $10.26. The firm’s 50-day moving average is $7.25 and its 200 day moving average is $5.78.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Abeona Therapeutics had a negative return on equity of 26.99% and a negative net margin of 2,568.57%. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, equities analysts forecast that Abeona Therapeutics will post ($0.57) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/abeona-therapeutics-inc-abeo-stock-rating-lowered-by-bidaskclub/1463562.html.

A number of hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC boosted its stake in Abeona Therapeutics by 50.0% in the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares in the last quarter. Family Management Corp bought a new stake in Abeona Therapeutics during the first quarter worth approximately $120,000. Hikari Power Ltd bought a new stake in Abeona Therapeutics during the first quarter worth approximately $150,000. Segantii Capital Management Ltd boosted its stake in Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 28,794 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 23,358 shares in the last quarter. Hedge funds and other institutional investors own 35.62% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.